Cardiovascular Morbidity and Mortality of the Metabolic Syndrome

Medical Clinics of North America

Volumn 91, Issue 6, 2007, Pages 1169-1184

  Obunai, Kotaro ^a   Jani, Sonal ^b   Dangas, George D ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; OBSERVATIONAL METHOD; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; MORBIDITY; SURVIVAL RATE; WORLD HEALTH;

EID: 35548964739     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.06.003     Document Type: Review

References (72)

1. Rosamond W., Flegal K., Friday G., et al., for the American Heart Association Statistics Committee and Stroke Statistics subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 17 (2005) 2735-2752
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
5. Alberti K.G.M.M., Zimmet P., Shaw J., et al., for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
6. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
7. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
8. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 19 (2002) 2570-2581
9. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 6 (2004) 2601-2607
10. Carmena R., Duriez P., and Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 III (2004) 2-7
11. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14 Suppl 1 (2006) 41S-49S
12. Williams S.B., Cusco J.A., Roddy M.A., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
13. Hopfner R.L., and Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42 (1999) 1383-1394
14. Nugent A.G., McGurk C., Hayes J.R., et al. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes 45 (1996) 105-107
15. Suzuki L.A., Poot M., Gerrity R.G., et al. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis. Diabetes 50 (2001) 851-860
16. Vinik A.I., Erbas T., Park T.S., et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476-1485
17. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15 (2001) 44-54
18. Ceriello A., Giacomello R., Stel G., et al. Hyperglycemia-induced thrombin formation in diabetes. Diabetes 44 (1995) 924-928
19. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
20. Festa A., D'Agostino Jr. R., Tracy R.P., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 1131-1137
21. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
22. Nesto R.W. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116 Suppl 5A (2004) 11S-22S
23. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
24. McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 28 (2005) 385-390
25. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
26. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
27. Katzmarzyk P.T., Church T.S., and Blair S.N. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164 (2004) 1092-1097
28. Malik S., Wong D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United Stated adults. Circulation 110 (2004) 1245-1250
29. Levantesi G., Macchia A., Marfisi R., et al., GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 46 2 (2005) 277-283
30. Kurl S., Laukkanen J.A., Niskanen L., et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37 3 (2006) 806-811
31. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-cause: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173 (2004) 309-314
32. Kip K.E., Marroquin O.C., Kelley D.E., et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Circulation 109 6 (2004) 706-713
33. Hunt K.J., Resendez R.G., Williams K., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
34. Galassi A., Reynolds K., and He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119 10 (2006) 812-819
35. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 4 (2007) 403-414
36. Bairey Merz C.N., Shaw L.J., Reis S.E., et al., WISE Investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 47 Suppl 3 (2006) S21-S29
37. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 18 (1998) 1837-1847
38. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
39. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 11 (2007) 1481-1501
40. Butler J., Rodondi N., Zhu Y., et al., Health ABC Study. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47 8 (2006) 1595-1602
41. Mohler E.R., Sheridan M.J., Nichols R., et al. Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study. Clin Cardiol 14 (1991) 995-999
42. Peltier M., Trojette F., Sarano M.E., et al. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 91 1 (2003) 97-99
43. Rajamannan N.M., Gersh B., and Bonow R.O. Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart 89 (2003) 801-805
44. Olsson M., Thyberg J., and Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 5 (1999) 1218-1222
45. Briand M., Lemieux I., Dumesnil J.G., et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47 11 (2006) 2229-2236
46. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
47. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 321 4 (2001) 225-236
48. Ärnlöv J., Lind L., Zethelius B., et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 142 (2001) 720-724
49. Devereux R.B., Roman M.J., Paranicas M., et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 101 (2000) 2271-2276
50. Rutter M.K., Parise H., Benjamin E.J., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107 (2003) 448-454
51. Ingelsson E., Arnlov J., Lind L., et al. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 92 10 (2006) 1409-1413
52. Lawlor D.A., Smith G.D., and Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 49 (2006) 41-48
53. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
54. Grundy S.M., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 13 (1999) 1481-1492
55. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., et al., CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 2 (2001) 180-187
56. Stern M.P., Williams K., Gonzalez-Villalpando C., et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care 27 11 (2004) 2676-2681
57. Wannamethee S.G., Shaper A.G., Lennon L., et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165 22 (2005) 2644-2650
58. Greenland P. Critical questions about the metabolic syndrome. Circulation 112 (2005) 3675-3676
59. Meigs J.B. Metabolic syndrome: in search of a clinical role. Diabetes Care 27 (2004) 2761-2763
60. Sattar N., and Forouhi N.G. Metabolic syndrome criteria: ready for clinical prime time or work in progress?. Eur Heart J 26 (2005) 1249-1251
61. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al., American Heart Association. National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 3 (2004) 433-438
62. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 (2006) 2130-2139
63. Buse J.B., Ginsberg H.N., Bakris G.L., et al., American Heart Association. American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 1 (2007) 114-126
64. Grundy S.M., Balady G.J., Criqui M.H., et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97 18 (1998) 1876-1887
65. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
66. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 (2007) S4-S41
67. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2572
68. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006) 791-798
69. Vasan R.S., Sullivan L.M., Wilson P.W., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 142 (2005) 393-402
70. Vasan R.S., and D'Agostino Sr. R.B. Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 111 (2005) 542-545
71. Ridker P.M., and Cook N. Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation 111 (2005) 657-658
72. Hu F.B., Stampfer M.J., Manson J.E., et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 343 (2000) 530-537